|

US has accepted 30 mln doses of hydroxychloroquine sulfate donated by Novartis's Sandoz as possible treatments for COVID-19

US HHS says it has accepted 30 mln doses of hydroxychloroquine sulfate donated by Novartis's Sandoz as possible treatments for COVID-19 patients.

Hydroxychloroquine, as well as a related drug, chloroquine, have been evaluated for use against COVID-19 in clinical trials around the world. Hydroxychloroquine is a derivative of chloroquine and is reported to be a less toxic form of the latter drug. US President Donald Trump has been in favour of the use of the chloroquine against the disease based on early data evaluating its efficacy against the novel coronavirus disease.

Key notes

  • US HHS says accepts donations of medicine to strategic national stockpile as possible treatments for COVID-19 patients.
  • US HHS says accepted 30 mln doses of hydroxychloroquine sulfate donated by Novartis's Sandoz as possible treatments for COVID-19 patients.
  • US HHS says accepted 1 mln doses of chloroquine phosphate donated by Bayer pharmaceuticals as possible treatments for COVID-19 patients.

Market implications

Watch and see. Markets are risk-off and taking each and every headline with respect to a cure with a pinch of salt. More on this here: US Pres. Trump: Working to speed up FDA approval on sterilizing medical masks for reuse

Author

Ross J Burland

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

More from Ross J Burland
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD moves sideways below 1.1800 on Christmas Eve

EUR/USD struggles to find direction and trades in a narrow channel below 1.1800 after posting gains for two consecutive days. Bond and stock markets in the US will open at the usual time and close early on Christmas Eve, allowing the trading action to remain subdued. 

GBP/USD keeps range around 1.3500 amid quiet markets

GBP/USD keeps its range trade intact at around 1.3500 on Wednesday. The Pound Sterling holds the upper hand over the US Dollar amid pre-Christmas light trading as traders move to the sidelines heading into the holiday season. 

Gold retreats from record highs, trades below $4,500

Gold retreats after setting a new record-high above $4,520 earlier in the day and trades in a tight range below $4,500 as trading volumes thin out ahead of the Christmas break. The US Dollar selling bias remains unabated on the back of dovish Fed expectations, which continues to act as a tailwind for the bullion amid persistent geopolitical risks.

Bitcoin slips below $87,000 as ETF outflows intensify, whale participation declines

Bitcoin price continues to trade around $86,770 on Wednesday, after failing to break above the $90,000 resistance. US-listed spot ETFs record an outflow of $188.64 million on Tuesday, marking the fourth consecutive day of withdrawals.

Economic outlook 2026-2027 in advanced countries: Solidity test

After a year marked by global economic resilience and ending on a note of optimism, 2026 looks promising and could be a year of solid economic performance. In our baseline scenario, we expect most of the supportive factors at work in 2025 to continue to play a role in 2026.

Avalanche struggles near $12 as Grayscale files updated form for ETF

Avalanche trades close to $12 by press time on Wednesday, extending the nearly 2% drop from the previous day. Grayscale filed an updated form to convert its Avalanche-focused Trust into an ETF with the US Securities and Exchange Commission.